<DOC>
	<DOCNO>NCT02732249</DOCNO>
	<brief_summary>Standard triple therapy include proton pump inhibitor ( PPI ) clarithromycin either amoxicillin metronidazole longer recommended empirical Ô¨Årst-line therapy treat Helicobacter pylori infection high antibiotic resistance . It unknown whether addition bismuth overcome antibiotic resistance . This study design evaluate efficacy safety addition bismuth standard triple therapy H. pylori first-line eradication .</brief_summary>
	<brief_title>Clarithromycin Triple Therapy Plus Bismuth Helicobacter Pylori First-line Treatment</brief_title>
	<detailed_description />
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Potassium Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Participants nonulcer functional dyspepsia scar peptic ulcer disease Ability willingness participate study sign give inform consent confirm H. pylorus infection Previous H. pylorus eradication therapy Less 18 year old With history H. pylori infection treatment With previous gastric surgery Major systemic disease Pregnancy lactation Allergy study drug Administration antibiotic , bismuth , antisecretory drug 8 week prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>Amoxicillin</keyword>
	<keyword>Metronidazole</keyword>
	<keyword>Eradication</keyword>
</DOC>